Research programme: c-Fms tyrosine kinase inhibitor - Kirin

Drug Profile

Research programme: c-Fms tyrosine kinase inhibitor - Kirin

Alternative Names: KI 20227; Ki20227

Latest Information Update: 21 Jan 2009

Price : $50

At a glance

  • Originator Kirin Brewery
  • Developer Kyowa Hakko Kirin
  • Class Quinolines; Small molecules
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bone disorders

Most Recent Events

  • 31 Dec 2008 Discontinued - Preclinical for Bone disorders in Japan (PO)
  • 21 Apr 2004 Preclinical trials in Bone disorders in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top